Tevogen (TVGN) announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility should support the Company’s cell therapy manufacturing operations. “Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” said Dr. Ryan Saadi, CEO of Tevogen Bio. “This facility has potential to efficiently scale our manufacturing as we advance our pipeline toward commercialization and will serve as a bridge as we enter the early stages of developing our own custom-built manufacturing facility.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- AI Daily: OpenAI said to end acquisition talks with Windsurf
- Tevogen.AI builds alpha version of PredicTcell model
- Tevogen Bio Grants Restricted Stock to CEO
- Tevogen Bio Holdings Enters $50M Sales Agreement
- Tevogen Bio CEO Contributes $500K for New HQ